IPOs: EyeGate tries again following deal with Valeant, Parkinson's specialist to debut soon

Israeli Parkinson's specialist Intec Pharma and drug delivery device maker EyeGate aim to debut on the Nasdaq this week for a combined $51 million.

Alnylam launches trial of one of its RNAi candidates

RNAi specialist Alnylam initiated Phase I/II trials of its candidate to treat AAT deficiency-associated liver disease (alpha-1 liver disease).

Pill holds a ring-shaped device that could deliver drugs to the stomach long-term

Researchers at MIT and Massachusetts General Hospital have designed an expanding pill that can be easily swallowed but can remain in the stomach potentially for months without obstructing normal gastrointestinal function.

ASU team offers precise DNA origami technique with novel shapes and delivery potential

Folding DNA into new, functional shapes isn't a new technique, but researchers at Arizona State University have demonstrated novel design methods that allow them an amount of control over the genetic substance never seen before, creating new three-dimensional shapes that could ultimately be used in drug delivery.

Germany's leon-nanodrugs GmbH bags $20M for its reformulation platform

Germany's leon-nanodrugs GmbH announced the closure of its €18.5 ($20.4 million) Series A preferred stock offering. The company develops oral and parenteral reformulations of generic active pharmaceutical ingredients using its patented MJR nanotechnology platform.

Ra Pharma gets $58.5M to challenge a rare disease's intravenous incumbent

Ra Pharma received $58.5 million from a mix of strategic and VC investors to take on Alexion's intravenously infused orphan drug Soliris with a cheaper, subcutaneously delivered alternative.

Two oral therapeutics specialists bag a combined $140M via IPO, VC funding

Although fancy technology is a big draw in drug delivery, the simple pill remains an allure, at least as a replacement for dreaded needles or cumbersome intravenous infusions.

Glucose delivery pathway that feeds tumors could be exploited to knock them down

New work from researchers at UCLA is shedding light on the delivery of glucose to tumor cells, particularly in pancreatic and prostate cancers. The research could offer new diagnostic procedures for detecting these cancers and, down the road, the use of inhibitors to cut down the amount of glucose delivered to the tumors, slowing down their growth.

Delcath bags orphan drug designation for drug/device combo to treat rare form of liver cancer

The FDA granted Delcath Systems orphan drug designation for its drug/delivery device combination product to treat liver cancer, including a rare form that affects fewer than 200,000 people in the U.S. The indication to treat intrahepatic cholangiocarcinoma will now receive favorable treatment from the FDA

Minimally invasive brain probe uses light flashes to target drugs

Researchers at Washington University iin St. Louis and the University of Illinois at Urbana-Champaign have overcome a common problem in drug delivery to the brain, which is to get the therapies to target certain brain circuits without accidentally affecting other parts of the brain or body.

Purdue team developing smart capsule for diseases of the large intestine

Purdue University researchers are developing a "smart" capsule to deliver drugs directly to the large intestine, bypassing the stomach and small intestine. It could have application to the treatment of irritable bowel syndrome, Crohn's disease and fighting the life-threatening bacteria Clostridium difficile, all conditions that affect the large intestine.

Novo to sell shield for concealing the needle of its injection pens

Novo Nordisk relies on improvements in its drug delivering injection pens to maintain and gain the market share of its injectables. To that end, the company just received FDA approval for its FlexPro PenMate to conceal the needle of injection pens used to administer its Norditropin for children and adults with growth hormone deficiency. It will be made commercially available in the second half of the year.

Eczema cream posts strong results in PhIII trial

Anacor Pharmaceuticals' topical treatment for eczema easily beat placebo in two Phase III trials, sending the biotech's share soaring and setting the stage for FDA application in the first of half of 2016. 

Researcher says more work needed on use of nanocarriers in fight against stroke, heart disease

A recent paper in Future Science provides an overview of clinical and preclinical nano- and microparticles and bubbles for carrying drugs to treat ischemic heart disease and stroke, with a goal of decreasing the rate of drugs' degradation in the blood and increasing the amount reaching the blood clot (or thrombus).

German team attacks cancer cell microtubules with chemo and blue light

German researchers have come up with an approach for chemotherapy that would allow the medication to be activated inside a patient when hit with light.

Parisian MIT spinoff pulls in €2M to fund CRISPR delivery work

Paris-based Eligo Bioscience pulled in €2 million in first-round financing to fund its ongoing efforts to target bacterial infections while sparing the healthy cells nearby. The technology is based on the booming CRISPR gene editing model, and the company is developing two lead candidates.

Valeant to commercialize and manufacture EyeGate's eye drug delivery device

Valeant Pharmaceuticals will commercialize and manufacture a delivery system and reformulated, topically active corticosteroid to treat uveitis developed EyeGate.

Neos files for $60M IPO with easy-to-swallow tablets for ADHD

Neos Therapeutics, a Dallas-area maker of extended-release formulations for ADHD that disintegrate in the mouth, announced that it aims to raise $60 million on the Nasdaq in an IPO planned for next week. The company expects to sell 4 million shares at $14 to $16 a pop.

Allergan buys dry-eye device startup for $125M+

Allergan is acquiring the startup Oculeve for $125 million. Oculeve's lead program is a clinical-stage dry-eye implant designed to stimulate natural tear production, which could replace the need for inconvenient lubricating eye drops.

Natural bioluminescence provides inside look at drug-cell interactions

Many sea creatures, like shrimp, employ bioluminescence in the dark depths of the ocean, and scientists at the Harry Perkins Institute of Medical Research are testing the proteins involved in that process to determine the way drugs interact with cells and help discover more efficient drug delivery methods.